CD200 in CNS tumor-induced immunosuppression: The role for CD200 pathway blockade in targeted immunotherapy

Journal for ImmunoTherapy of Cancer

Volumn 2, Issue 1, 2014, Pages

  Moertel, Christopher L ^a   Xia, Junzhe ^a,b   LaRue, Rebecca ^a   Waldron, Nate N ^a   Andersen, Brian M ^a   Prins, Robert M ^c   Okada, Hideho ^d   Donson, Andrew M ^e   Foreman, Nicholas K ^e   Hunt, Matthew A ^f   Pennell, Christopher A ^a   Olin, Michael R ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b CHINA MEDICAL UNIVERSITY   (China)

^c UCLA MEDICAL CENTER   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

^e University of Colorado Denver and Children s Hospital Colorado   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Brain tumors; Checkpoint inhibitors; Immune suppression; Immunotherapy

Indexed keywords

CD200 ANTIGEN; CD200 RECEPTOR; MESSENGER RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CENTRAL NERVOUS SYSTEM TUMOR; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; GLIOBLASTOMA; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RAT; SIGNAL TRANSDUCTION; TISSUE MICROARRAY; WESTERN BLOTTING;

EID: 84977123380     PISSN: None     EISSN: 20511426     Source Type: Journal    
DOI: 10.1186/s40425-014-0046-9     Document Type: Article

References (37)

1. Kerkar SP, Restifo NP. Cellular constituents of immune escape within the tumor microenvironment. Cancer Res 2012, 72(13):3125-3130. 10.1158/0008-5472.CAN-11-4094, 22721837.
2. Anandkumar A, Devaraj H. Tumour immunomodulation: mucins in resistance to initiation and maturation of immune response against tumours. Scand J Immunol 2013, 78(1):1-7. 10.1111/sji.12019, 23298229.
3. Gajewski TF, Meng Y, Blank C, Brown I, Kacha A, Kline J, Harlin H. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev 2006, 213:131-145. 10.1111/j.1600-065X.2006.00442.x, 16972901.
4. Callahan MK, Wolchok JD. At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy. J Leukoc Biol 2013, 94(1):41-53. 10.1189/jlb.1212631, 23667165.
5. Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci U S A 2010, 107(9):4275-4280. 10.1073/pnas.0915174107, 20160101.
6. Chitnis T, Imitola J, Wang Y, Elyaman W, Chawla P, Sharuk M, Raddassi K, Bronson RT, Khoury SJ. Elevated neuronal expression of CD200 protects Wlds mice from inflammation-mediated neurodegeneration. Am J Pathol 2007, 170(5):1695-1712. 10.2353/ajpath.2007.060677, 17456775.
7. Koning N, Swaab DF, Hoek RM, Huitinga I. Distribution of the immune inhibitory molecules CD200 and CD200R in the normal central nervous system and multiple sclerosis lesions suggests neuron-glia and glia-glia interactions. J Neuropathol Exp Neurol 2009, 68(2):159-167. 10.1097/NEN.0b013e3181964113, 19151626.
8. Hoek RM, Ruuls SR, Murphy CA, Wright GJ, Goddard R, Zurawski SM, Blom B, Homola ME, Streit WJ, Brown MH, Barclay AN, Sedgwick JD. Down-regulation of the macrophage lineage through interaction with OX2 (CD200). Science 2000, 290(5497):1768-1771. 10.1126/science.290.5497.1768, 11099416.
9. Gorczynski R, Boudakov I, Khatri I. Peptides of CD200 modulate LPS-induced TNF-alpha induction and mortality in vivo. J Surg Res 2008, 145(1):87-96. 10.1016/j.jss.2007.04.043, 17981299.
10. Gorczynski R, Chen Z, Kai Y, Lee L, Wong S, Marsden PA. CD200 is a ligand for all members of the CD200R family of immunoregulatory molecules. J Immunol 2004, 172(12):7744-7749. 10.4049/jimmunol.172.12.7744, 15187158.
11. Wright GJ, Cherwinski H, Foster-Cuevas M, Brooke G, Puklavec MJ, Bigler M, Song Y, Jenmalm M, Gorman D, McClanahan T, Liu MR, Brown MH, Sedgwick JD, Phillips JH, Barclay AN. Characterization of the CD200 receptor family in mice and humans and their interactions with CD200. J Immunol 2003, 171(6):3034-3046. 10.4049/jimmunol.171.6.3034, 12960329.
12. Gorczynski RM, Chen Z, Clark DA, Kai Y, Lee L, Nachman J, Wong S, Marsden P. Structural and functional heterogeneity in the CD200R family of immunoregulatory molecules and their expression at the feto-maternal interface. Am J Reprod Immunol 2004, 52(2):147-163. 10.1111/j.1600-0897.2004.00192.x, 15274657.
13. Gorczynski RM. CD200 and its receptors as targets for immunoregulation. Curr Opin Investig Drugs 2005, 6(5):483-488. 15912961.
14. Stumpfova M, Ratner D, Desciak EB, Eliezri YD, Owens DM. The immunosuppressive surface ligand CD200 augments the metastatic capacity of squamous cell carcinoma. Cancer Res 2010, 70(7):2962-2972. 10.1158/0008-5472.CAN-09-4380, 20332223.
15. Holmannova D, Kolackova M, Kondelkova K, Kunes P, Krejsek J, Andrys C. CD200/CD200R paired potent inhibitory molecules regulating immune and inflammatory responses; Part I: CD200/CD200R structure, activation, and function. Acta Medica (Hradec Kralove) 2012, 55(1):12-17.
16. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics 2008, 1:52. 10.1186/1755-8794-1-52, 18940004.
17. Freije W, Castro-Vargas F, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. Gene expression profiling of gliomas strongly predicts survival. Cancer Research 2004, 64(18):6503-6510. 10.1158/0008-5472.CAN-04-0452, 15374961.
18. Prins RM, Soto H, Konkankit V, Odesa SK, Eskin A, Yong WH, Nelson SF, Liau LM. Gene expression profile correlates with T-cell infiltration and relative survival in glioblastoma patients vaccinated with dendritic cell immunotherapy. Clin Cancer Res 2011, 17(6):1603-1615. 10.1158/1078-0432.CCR-10-2563, 21135147.
19. Witt H, Mack SC, Ryzhova M, Bender S, Sill M, Isserlin R, Benner A, Hielscher T, Milde T, Remke M, Jones DT, Northcott PA, Garzia L, Bertrand KC, Wittmann A, Yao Y, Roberts SS, Massimi L, Van Meter T, Weiss WA, Gupta N, Grajkowska W, Lach B, Cho YJ, von Deimling A, Kulozik AE, Witt O, Bader GD, Hawkins CE, Tabori U, et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. Cancer Cell 2011, 20(2):143-157. 10.1016/j.ccr.2011.07.007, 21840481.
20. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012, 123(4):465-472. 10.1007/s00401-011-0922-z, 22134537.
21. Petermann KB, Rozenberg GI, Zedek D, Groben P, McKinnon K, Buehler C, Kim WY, Shields JM, Penland S, Bear JE, Thomas NE, Serody JS, Sharpless NE. CD200 is induced by ERK and is a potential therapeutic target in melanoma. J Clin Invest 2007, 117(12):3922-3929. 18008004.
22. Kawasaki BT, Farrar WL. Cancer stem cells, CD200 and immunoevasion. Trends Immunol 2008, 29(10):464-468. 10.1016/j.it.2008.07.005, 18775673.
23. Wong KK, Brenneman F, Chesney A, Spaner DE, Gorczynski RM. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice. Cancer Res 2012, 72(19):4931-4943. 10.1158/0008-5472.CAN-12-1390, 22875025.
24. Olin M, Low W, McKenna D, Haines S, Dahlheimer T, Nascene D, Gustafson M, Dietz A, Clark B, Chen W, Blazar B, Ohlfest JR, Moertel C. Vaccination with Dendritic Cells Loaded with Allogeneic Brain Tumor Cells for Recurrent Malignant Brain Tumors Induce a CD4 + IL17+ Response. J Immunother Cancer 2014, 2:4. 10.1186/2051-1426-2-4, 24829761.
25. Ohlfest JR, Andersen BM, Litterman AJ, Xia J, Pennell CA, Swier LE, Salazar AM, Olin MR. Vaccine injection site matters: qualitative and quantitative defects in CD8 T cells primed as a function of proximity to the tumor in a murine glioma model. J Immunol 2013, 190(2):613-620. 10.4049/jimmunol.1201557, 23248259.
26. Kirkwood JM, Butterfield LH, Tarhini AA, Zarour H, Kalinski P, Ferrone S. Immunotherapy of cancer in 2012. CA Cancer J Clin 2012, 62(5):309-335. 10.3322/caac.20132, 22576456.
27. Janne PA. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations. Semin Oncol 2005, 32(6 Suppl 10):S9-S15. 10.1053/j.seminoncol.2005.10.004, 16459174.
28. Forde PM, Kelly RJ, Brahmer JR. New Strategies in Lung Cancer: Translating Immunotherapy into Clinical Practice. Clin Cancer Res 2014, 20(5):1067-1073. 10.1158/1078-0432.CCR-13-0731, 24470514.
29. Mantovani A, Sica A, Allavena P, Garlanda C, Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009, 70(5):325-330. 10.1016/j.humimm.2009.02.008, 19236898.
30. Hoffman LM, Donson AM, Nakachi I, Griesinger AM, Birks DK, Amani V, Hemenway MS, Liu AK, Wang M, Hankinson TC, Handler MH, Foreman NK. Molecular sub-group-specific immunophenotypic changes are associated with outcome in recurrent posterior fossa ependymoma. Acta Neuropathol 2014, 127(5):731-745. 10.1007/s00401-013-1212-8, 24240813.
31. Ramaswamy V, Remke M, Bouffet E, Faria CC, Perreault S, Cho YJ, Shih DJ, Luu B, Dubuc AM, Northcott PA, Schüller U, Gururangan S, McLendon R, Bigner D, Fouladi M, Ligon KL, Pomeroy SL, Dunn S, Triscott J, Jabado N, Fontebasso A, Jones DT, Kool M, Karajannis MA, Gardner SL, Zagzag D, Nunes S, Pimentel J, Mora J, Lipp E, et al. Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncol 2013, 14(12):1200-1207. 10.1016/S1470-2045(13)70449-2, 24140199.
32. Murdoch C, Muthana M, Coffelt S, Lewis C. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008, 8:618-631. 10.1038/nrc2444, 18633355.
33. Weber J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin Oncol 2010, 37(5):430-439. 10.1053/j.seminoncol.2010.09.005, 21074057.
34. Kretz-Rommel A, Qin F, Dakappagari N, Cofiell R, Faas SJ, Bowdish KS. Blockade of CD200 in the presence or absence of antibody effector function: implications for anti-CD200 therapy. J Immunol 2008, 180(2):699-705. 10.4049/jimmunol.180.2.699, 18178807.
35. Donson AM, Birks DK, Barton VN, Wei Q, Kleinschmidt-Demasters BK, Handler MH, Waziri AE, Wang M, Foreman NK. Immune gene and cell enrichment is associated with a good prognosis in ependymoma. J Immunol 2009, 183(11):7428-7440. 10.4049/jimmunol.0902811, 19917695.
36. Olin MR, Andersen BM, Zellmer DM, Grogan PT, Popescu FE, Xiong Z, Forster CL, Seiler C, SantaCruz KS, Chen W, Blazar BR, Ohlfest JR. Superior efficacy of tumor cell vaccines grown in physiologic oxygen. Clin Cancer Res 2010, 16(19):4800-4808. 10.1158/1078-0432.CCR-10-1572, 20858839.
37. Xiong Z, Gharagozlou S, Vengco I, Chen W, Ohlfest JR. Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis. Clin Cancer Res 2008, 14(17):5484-5493. 10.1158/1078-0432.CCR-07-4139, 18765540.